TrialArthritis research & therapy2014

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.

Paolo Fraticelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.